

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# ClouDr Group Limited

## 智雲健康科技集團\*

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9955)**

### **VOLUNTARY ANNOUNCEMENT**

### **STRATEGIC COOPERATION AGREEMENT WITH ANPRIME BIO**

This announcement is made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis. The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on January 26, 2024, the Company entered into a non-legally binding strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with 杭州安元生物醫藥科技有限公司 (Hangzhou Anprime BioPharm Co. Ltd.\*) (“**Anprime Bio**”).

Established in 2016, Anprime Bio is a speciality pharmaceutical company principally engaged in the research and development of innovative drugs based on polymer compounds and generic drugs with technological barriers. The therapeutic areas of the drugs researched and developed by Anprime Bio mainly include renal diseases, liver and gallbladder diseases, cardiovascular diseases and gastrointestinal diseases, etc., and the main target markets of such drugs include the People’s Republic of China, the United States and other regulated markets.

Pursuant to the Strategic Cooperation Agreement, the Group will become the exclusive distributor of Anprime Bio’s Sevelamer Carbonate for Oral Suspension® products in China for a term of ten years. The applicable users of the drug require long-term medication, which largely overlap with the coverage of the Company’s chronic disease management business and hospital SaaS. During the term of cooperation, the parties will leverage the digitalization capabilities of the Group’s hospital SaaS to cooperate in respect of the marketing promotion and product sales of the Sevelamer Carbonate for Oral Suspension® products, with a view to exploring a wider market for the Sevelamer Carbonate for Oral Suspension® products and enhancing the promotional efficiency through the business cooperation. Based on the innovativeness and the clinical value of the drug, Anprime Bio chose to apply for approvals from both National Medical Products Administration of China (“**NMPA**”) and the United States Food and Drug Administration (“**FDA**”), and the drug has been approved by NMPA

and FDA now, which opens up the possibility for the Group to develop overseas sales channels of the drug.

The Board is of the view that the Strategic Cooperation Agreement provides valuable opportunities for the parties to utilize their respective resources and expertise to create mutual benefits and synergies for each other. Accordingly, the Board is of the view that the entering into of the Strategic Cooperation Agreement is in the interests of the Company and its shareholders as a whole.

### **INFORMATION ON SEVELAMER CARBONATE FOR ORAL SUSPENSION® (Guoyaozhunzi (國藥准字) H20243077)**

Sevelamer Carbonate is a synthetic non-calcium, non-metallic phosphate binding agent that works by binding phosphorus in the gastrointestinal tract and decreasing its absorption, resulting in lower blood phosphate concentrations. It is used clinically for the treatment of hyperphosphatemia in adult patients with chronic kidney disease who are on dialysis and in adult patients with chronic kidney disease whose serum phosphorus is  $\geq 1.78$  mmol/L but who are not on dialysis. As of now, only Sevelamer Carbonate tablets are available in the Chinese market. According to data published by [www.yaozh.com](http://www.yaozh.com), hospital sales of Sevelamer Carbonate tablets in China reached RMB708 million in 2022, representing a 50% increase from 2021. Sevelamer Carbonate tablets need to be swallowed in whole, which is not friendly to adult and pediatric patients with dysphagia, and the oral suspension can be an effective solution to dysphagia without compromising clinical efficacy of the drug. Anprime Bio's Sevelamer Carbonate for Oral Suspension® is the first generic and exclusive product in China and is expected to have a long product life cycle.

To the best of the Board's knowledge, information and belief after having made all reasonable enquiries, Anprime Bio is a third party independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). The Company will comply with the Listing Rules and make further announcement on the potential cooperation as and when appropriate. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board  
**ClouDr Group Limited**  
**Kuang Ming**

*Chairman, Executive Director and Chief Executive Officer*

Hong Kong, January 26, 2024

*As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.*

\* *For identification purpose only*